CN111820409A - Composition for relieving visual fatigue and preparation method thereof - Google Patents
Composition for relieving visual fatigue and preparation method thereof Download PDFInfo
- Publication number
- CN111820409A CN111820409A CN201910316791.1A CN201910316791A CN111820409A CN 111820409 A CN111820409 A CN 111820409A CN 201910316791 A CN201910316791 A CN 201910316791A CN 111820409 A CN111820409 A CN 111820409A
- Authority
- CN
- China
- Prior art keywords
- parts
- astaxanthin
- olive oil
- soft capsule
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 17
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 44
- 239000001168 astaxanthin Substances 0.000 claims abstract description 44
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 44
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 44
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 44
- 239000004006 olive oil Substances 0.000 claims abstract description 37
- 235000008390 olive oil Nutrition 0.000 claims abstract description 37
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000007901 soft capsule Substances 0.000 claims description 30
- 108010010803 Gelatin Proteins 0.000 claims description 15
- 239000008273 gelatin Substances 0.000 claims description 15
- 229920000159 gelatin Polymers 0.000 claims description 15
- 235000019322 gelatine Nutrition 0.000 claims description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 239000008213 purified water Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 31
- 230000004310 photopic vision Effects 0.000 abstract description 19
- 230000002688 persistence Effects 0.000 abstract description 16
- 206010015958 Eye pain Diseases 0.000 abstract description 3
- 206010015967 Eye swelling Diseases 0.000 abstract description 3
- 206010023644 Lacrimation increased Diseases 0.000 abstract description 3
- 206010034960 Photophobia Diseases 0.000 abstract description 3
- 206010047513 Vision blurred Diseases 0.000 abstract description 3
- 230000004317 lacrimation Effects 0.000 abstract description 3
- 230000035807 sensation Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 44
- 235000013305 food Nutrition 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000001035 drying Methods 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 235000021195 test diet Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011976 chest X-ray Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 244000062645 predators Species 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a composition for relieving visual fatigue, which consists of astaxanthin and olive oil in a weight ratio of 1: 0.4-40. The composition can effectively improve symptoms of eye ache, eye swelling, photophobia, blurred vision, dry and wet eyes, foreign body sensation, lacrimation and the like, obviously improves photopic vision persistence, and has a total effective rate of 70.2%.
Description
Technical Field
The invention relates to a composition for relieving visual fatigue and a preparation method thereof, belonging to the field of medicine and health care.
Background
Astaxanthin is a carotenoid, and is the highest-grade product of carotenoid synthesis, is widely present in the living world, particularly in feathers of shrimps, crabs, fish, algal bodies, yeasts and birds, and is one of the main carotenoids in marine organisms. Astaxanthin is one of the strongest antioxidants in the world, and is capable of effectively eliminating oxygen radicals in cells, enhancing the cell regeneration capacity, maintaining the balance of the organism and reducing the accumulation of aging cells, thereby protecting the health of skin, promoting the growth of hair, resisting aging, enhancing the immunity and relieving asthenopia.
Disclosure of Invention
The invention aims to provide a composition for relieving visual fatigue and a preparation method thereof.
As one aspect of the present invention, the present invention provides a composition for relieving asthenopia, which comprises astaxanthin and olive oil in a weight ratio of 1: (0.4-40).
Preferably, the composition is prepared from astaxanthin and olive oil in a weight ratio of 1: (0.4-4).
Further preferably, the composition is prepared from astaxanthin and olive oil in a weight ratio of 1: 0.4 or 1: 4.
The composition can be added with conventional auxiliary materials and prepared into oral dosage forms according to the conventional preparation process, such as granules, tablets, soft capsules, dripping pills, oral liquid, suspension, emulsion and the like.
The conventional auxiliary materials comprise: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crospolyvinylpyrrolidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, etc.; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the adhesive comprises: starch slurry, polyvinylpyrrolidone, hydroxypropylmethylcellulose, and the like; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like; the flavoring agent comprises: sweeteners and various essences; the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.; the matrix comprises: PEG6000, PEG4000, insect wax, etc.
As another aspect of the invention, the invention provides application of the composition in preparing a medicine or health-care product for relieving visual fatigue or dry eye.
In a third aspect of the present invention, there is provided a soft capsule for relieving asthenopia, the content of the soft capsule comprises astaxanthin and olive oil, the weight ratio of astaxanthin to olive oil is 1: (0.4-40).
Preferably, the weight ratio of the astaxanthin to the olive oil is 1: (0.4-4).
Further preferably, the content of the soft capsule consists of the following raw materials: 80-130 parts of astaxanthin and 430 parts of olive oil; the capsule shell is composed of the following raw materials: 470 and 540 parts of gelatin, 220 and 280 parts of glycerol and 470 and 540 parts of purified water.
Still more preferably, the content of the soft capsule consists of the following raw materials: 90-120 parts of astaxanthin and 420 parts of olive oil 370-; the capsule skin comprises the following raw materials: 480 parts of gelatin, 270 parts of glycerol, and 480 parts of purified water;
or the content of the soft capsule consists of the following raw materials: 95-110 parts of astaxanthin and 410 parts of olive oil; the capsule skin comprises the following raw materials: 510 parts of gelatin 490-containing material, 260 parts of glycerol 240-containing material and 510 parts of purified water 490-containing material.
Most preferably, the soft capsule contents consist of the following raw materials: 100 parts of astaxanthin and 400 parts of olive oil; the capsule skin comprises the following raw materials: 500 parts by weight of gelatin, 250 parts by weight of glycerol and 500 parts by weight of purified water.
As a fourth aspect of the present invention, the present invention provides a method for preparing a soft capsule of the composition, the method comprising the steps of:
step a, preparation of contents: mixing astaxanthin and olive oil to obtain a content material liquid for later use;
step b, sol: weighing according to a certain proportion, firstly adding purified water and glycerol, heating and stirring, then adding gelatin until the gelatin is completely dissolved for later use;
step c, pelleting: and c, pelleting and shaping the content prepared in the step a and the glue solution prepared in the step b to prepare the soft capsule.
Preferably, after mixing the purified water and glycerol of step b, adding gelatin at 70-80 ℃;
preferably, the preparation method further comprises a step d of drying, wherein the drying temperature is 22-28 ℃, the humidity is 20-30%, and the drying time is 24-48 hours.
The research of the invention shows that the composition can effectively improve the symptoms of eye ache, eye swelling, photophobia, blurred vision, dry and wet eyes, foreign body sensation, lacrimation and the like, obviously improve the photopic vision persistence, has the total effective rate of 70.2 percent, and is obviously higher than that of a control group.
Detailed Description
Example 1
The formula is as follows:
the preparation method comprises the following steps:
step a, preparation of contents: mixing astaxanthin and olive oil, stirring uniformly, vacuumizing (vacuum degree of-0.06 to-0.08 Mpa), removing bubbles, and filtering with a 100-mesh sieve. Obtaining content material liquid, and placing the content material liquid in a container for later use;
step b, sol: weighing according to a certain proportion, firstly adding purified water and glycerol, heating and stirring, adding gelatin at 70-80 deg.C until the gelatin is completely dissolved. Stirring for about 1 hour, vacuumizing (vacuum degree of-0.06 to-0.08 Mpa), removing bubbles, filtering with a 100-mesh sieve, and keeping the temperature at 60 +/-5 ℃ for later use;
step c, pelleting: c, pelleting and shaping the content prepared in the step a and the glue solution prepared in the step b to prepare soft capsules;
step d, drying: placing the shaped soft capsule in a drying room, controlling the indoor temperature at 22-28 deg.C, controlling the humidity at 20-30%, and drying for about 24 hr.
Example 2
The formula is as follows:
the preparation method is the same as example 1.
Example 3
The formula is as follows:
the preparation method is the same as example 1.
Example 4
The formula is as follows:
the preparation method is the same as example 1.
Example 5
The formula is as follows:
the preparation method is the same as example 1.
EXAMPLE 6 screening of oils
The edible oil has good solubility to fat-soluble components, has the characteristics of high vapor pressure, low volatility, edible safety and the like, and is suitable for serving as a soft capsule matrix component. Soft capsules were prepared according to the method and formulation of example 1 using soybean oil, olive oil and PEG400 as solvents, respectively, and the solubility of astaxanthin in soybean oil, olive oil and PEG400 was examined.
Preparation and linear relationship examination of control solutions: accurately weighing 2mg astaxanthin reference substance, dissolving with anhydrous ethanol and fixing volume to 20mL measuring flask, respectively accurately transferring to 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2mL, diluting with anhydrous ethanol and fixing volume to 10mL measuring flask, measuring light absorption at 478nmValues were plotted on the ordinate and concentration on the abscissa to obtain a standard curve, and the regression equation Y was 83.64X +0.0054, R2When the concentration of the astaxanthin control sample is 0.9985, the linear relation is good in the range of 1-12 mug/mL.
Accurately weighing appropriate amount of astaxanthin, respectively adding into equal amount of soybean oil, oleum Olivarum and PEG400, dissolving, performing ultrasonic treatment at room temperature for 30min, centrifuging to separate supernatant and precipitate, and measuring and calculating astaxanthin extraction rate. The results are shown in Table 1.
TABLE 1 measurement results of astaxanthin extraction rates in different solvents
Soybean oil | Olive oil | PEG400 | |
Astaxanthin extraction yield (%) | 69.65 | 75.42 | 48.33 |
Compared with the solubility of the three solvents to the astaxanthin, the dissolution effect of the soybean oil and the olive oil as the solvents to the astaxanthin is determined to be better, the solubility of the solvent with the same amount is higher, the astaxanthin ingredients are mixed more uniformly in the capsule, the precipitation risk is lower, the olive oil is rich in nutrition and higher in functional value, and the olive oil is selected as the solvent of the astaxanthin.
Example 7 verification of the ratio of olive oil to astaxanthin
Particularly, olive oil contains a large amount of polyunsaturated fatty acids (PUFA) and is more susceptible to oxygen, so that the astaxanthin can be used to inhibit the oxidative rancidity of the fatty acids in olive oil, and the optimal addition ratio of the astaxanthin can be determined by measuring the peroxide value of the olive oil at different times, thereby ensuring the optimal antioxidant activity.
Placing 30mL of oleum Olivarum in 50mL conical flask, numbers 1, 2, 3, 4, 5, and 6, wherein number 1 is control, and numbers 2-6 are added with 0.0075, 0.075, 0.75, 7.5, and 75g astaxanthin oil respectively. Each sample was placed in an oven at 60 ℃ and the peroxide value was measured daily (24 h). The results are shown in Table 2.
TABLE 2 verification of the olive oil to astaxanthin ratio
The experimental result shows that the group 5 (adding 7.5 g of astaxanthin oil in 30ml of olive oil) can achieve the best antioxidation result, the antioxidation effect is not obviously increased when the group 5 is continuously added, the cost is increased, and the significance is small. And (3) fixing natural astaxanthin: the ratio of olive oil is 1: 4.
EXAMPLE 8 Effect test
1 materials and methods
1.1 sample: composition softgels (prepared as in example 1). It is administered orally 2 times a day, 1 granule each time.
1.2 subjects: selecting the subjects with asthenopia symptoms of 18-65 years old according to the self-induction principle.
1.2.1 Inclusion criteria: adults 18-65 years old, and people with long-term eye use and easy fatigue of vision.
1.2.2 exclusionary criteria
1.2.2.1 patients with infectious, traumatic eye disease. Eye surgery is performed for less than 3 months.
1.2.2.2 patients with internal and external eye diseases such as cornea, vitreous body, eyeground pathological changes, and the like.
1.2.2.3 patients with cardiovascular, cerebrovascular, hepatic, renal, hematopoietic system diseases.
1.2.2.4 pregnant or lactating women, allergic constitution patients.
1.2.2.5 taking the article related to the tested function in a short time affects the judger of the result.
1.2.2.6 it can be used for treating vision diseases by long-term administration of medicine, health product, or other treatment method.
1.2.2.7 not meeting the inclusion criteria, not eating the test substance as specified, or the data is not complete and affects the efficacy or safety judgment.
1.3 Experimental design and grouping
Two control designs, self and group, were used. Grouping according to random and double-blind requirements, and balancing the symptoms and vision level of the trial group and the control group according to the symptoms and vision examination conditions during grouping. Meanwhile, factors such as age, sex and the like are considered, so that the two groups have comparability. The number of the test subjects in each group is not less than 50 at the end of the feeding trial.
1.4 dosage and time
The test group took the soft capsules prepared in example 12 times a day, 1 capsule each time, and took orally. The control group received placebo. The subject is administered for 60 consecutive days. The subject stopped taking medications or other health care products related to improving vision during the feeding period.
1.5 instruments and reagents
Hitachi 7180 full-automatic biochemical analyzer (CENTRONIC, Germany); DIRUIH-300 urine eight item Analyzer (Changdui corporation); Sysmex-K21 three-class blood analyzer (Sysmex corporation); sysmex hemocyte analysis diluent (Sysmex corporation); DIRUI urinalysis reagent strips (vinddi); ridman biochemical kit (beijing ridman biochemical corporation), japan cooperative biochemical kit (japan cooperative medical corporation), and japan biochemical kit (japan chemical corporation).
2 observation index
2.1 efficacy index
2.1.1 questionnaire: symptom inquiry, eye (computer, television, book and newspaper) condition.
2.1.2 ophthalmic examinations: including fundus examination, vision examination (myopia, hyperopia, astigmatism, etc.).
2.1.3 photopic Vision persistence detection
The photopic vision persistence measuring method comprises drawing a 'pin' -shaped three-dimensional block diagram on a check table, wherein each side of each block is a centimeter, and the local illumination is 100-150LX (a specially manufactured lamp box can be used). The distance between the checklist and the eyes should be kept at a proper distance according to the visual habit of the subject, and the subject is defined to see the character "Pin" as photopic vision, and to be not photopic vision when the character "Pin" is inverted, and the measurement time is 3 minutes.
Photopic vision duration ═ 100% (photopic vision time/total fixation time)%
2.2 safety indices
2.2.1 routine examination of blood, urine and feces
Erythrocyte count, hemoglobin, leukocyte count, urine ten-item test and stool microscopic examination.
2.2.2 Biochemical index determination
Serum albumin (AIb), Total Protein (TP), liver and kidney functions (aspartate Aminotransferase (AST), alanine Aminotransferase (ALT), Urea (Urea), creatinine (Cre), blood glucose (GIu), blood lipids (total cholesterol (TC), and Triglycerides (TG).
2.2.3 Abdominal ultrasonography B, electrocardiogram, X-ray chest fluoroscopy (one examination before taking test).
2.3 efficacy determination
2.3.1 effective rate for improving symptoms
The symptoms of the eye are 3 improved in 8 symptoms of eye ache, eye swelling, photophobia, blurred vision, dry and wet eyes, foreign body sensation, lacrimation and general discomfort, and the symptoms are judged to be improved if other symptoms are not worsened. Two groups of symptom improvement cases and two groups of symptom improvement effective rates are calculated. The effective rate (%) for symptom improvement was calculated as 100 test food examples of symptom improvement. The two groups of symptoms are tested for improving the effective rate statistically.
2.3.2 mean integral of symptoms
And calculating symptom integrals of each test taker before and after the test eating, respectively calculating average integral values of the two groups, and performing statistical test. The scoring criteria are shown in table 3.
TABLE 3 asthenopia symptom determination method
Note: "occasionally" means 1-2 times per day; "occasionally" means 1-3 times per day; "often" means > 3 times per day
2.3.3 photopic Vision persistence
Compared with the test group or the test group and the control group, the photopic vision persistence difference is significant (P is less than 0.05), and the improvement of the average photopic vision persistence is more than or equal to 10 percent, which is effective.
2.4 statistical analysis of data
The metrology data can be analyzed using a t-test. Paired t-tests were used for self-control and grouped t-tests were used for two-panel mean comparisons. And (3) carrying out appropriate variable conversion on the data with abnormal distribution or variance, carrying out t test on the converted data after the converted data meets the normal variance, and carrying out t test or rank sum test on the converted data if the converted data still can not meet the normal variance requirement. On the premise that the comparison difference between groups before test feeding is not significant, comparison between groups after test can be carried out.
X for counting data2And (6) checking. And when the total case number of the four-table is less than 40 or the total case number is equal to or more than 40 but the theoretical frequency is equal to or less than 1, the exact probability method is applied.
2.5 determination of results
2.5.1 compared with the test group or the test group and the control group, the effective rate of improving symptoms or the difference of total score of symptoms is significant (P < 0.05).
2.5.2 compared with the test group or the test group and the control group, the photopic vision persistence difference is significant (P is less than 0.05), and the average photopic vision persistence is improved by more than or equal to 10%.
2.5.1 and 2.5.2, and the rate of improvement of vision is not significantly reduced, and it can be judged that the test substance has the function of contributing to the alleviation of asthenopia.
3 results of the experiment
3.1 Observation of efficacy
3.1.1 general conditions
118 subjects were included and randomized into a test diet group and a control group. The subjects who are deprived of test are 2 in each of the diet group and the control group, 114 effective subjects, 57 test diet groups and 57 control groups, the examinations of blood routine, urine routine, stool routine, liver and kidney functions, chest X-ray, electrocardiogram, B-ultrasound and the like of the subjects before the test are in a normal range, and the ages, sexes, photopic persistence, vision, total integral of symptoms and eye time of the subjects in the two groups before the test are not obviously different (P is more than 0.05), so that the subjects have comparability. The predator has no obvious changes in spirit, sleep, diet, defecation and the like before and after the predator takes the test.
3.1.2 Change in Total integral of symptoms
The results are shown in Table 4.
Group of | Number of examples | Before tasting | After eating trial |
Test food group | 57 | 16.19±2.16 | 12.93±2.90***### |
Control group | 57 | 16.04±2.16 | 15.81±2.29 |
Self comparison of P <0.001, between # groups of P <0.001
The results show that the total symptom score is obviously improved (P is less than 0.001) by comparing the test food group with the control group before and after the test food group tests the food and comparing the test food group with the control group.
3.1.3 improvement of the Primary symptoms
The results are shown in Table 5.
TABLE 5 improvement of the chief complaints
3.1.4 photopic Vision persistence Change
The results are shown in Table 6.
Self comparison of P <0.001, between # groups of P <0.001
The photopic vision persistence is improved by comparing the test group with the control group before and after the test, and the differences are obvious (P is less than 0.001); after the test diet, the average photopic vision persistence is improved by 10.1 percent, and is obviously different (P is less than 0.001) compared with that of a control group.
3.1.5 effective rate for improving symptoms
The results are shown in Table 7.
Table 7 results of total effective rate improvement of symptoms before and after test eating
Group of | Number of examples | Effective number of cases | Number of invalid cases | Effective rate (%) |
Test food group | 57 | 40 | 17 | 70.2### |
Control group | 57 | 1 | 56 | 1.8 |
Comparison between # group P <0.001
The total symptoms after the test eating are 40 cases, the total effective rate is 70.2 percent, and the obvious difference is compared with a control group (P is less than 0.001).
3.2 safety observations
The blood routine, the urine routine, the stool routine, the blood biochemical index and the electrocardiogram are normal before and after the test, and the chest fluoroscopy by x-ray is normal, and no adverse reaction is seen in the two groups.
4 small knot
4.1118 visual fatigue test subjects meeting the requirements are randomly divided into a test food group and a control group, 114 effective test subjects, 57 test food groups and 57 control groups. The control group received placebo. After the test group orally takes the composition soft capsules prepared in example 1 as required for 60 days, the total integral of symptoms is obviously improved (P is less than 0.001) by comparing the test group with the control group before and after test eating. The total symptoms after the test eating are 40 cases, the total effective rate is 70.2 percent, and the obvious difference is compared with a control group (P is less than 0.001). The photopic vision persistence is improved by comparing the test group with the control group before and after the test, and the differences are obvious (P is less than 0.001); after the test diet, the average photopic vision persistence is improved by 10.1 percent, and is obviously different (P is less than 0.001) compared with that of a control group. According to the judgment standard of the function of relieving the asthenopia in the national food and drug administration of food and drug supervision and protection No. 2012/107 annex 4, the result shows that the composition soft capsule prepared by the invention has the function of relieving the asthenopia.
4.2 the chest X-ray, abdomen B-ultrasonic, electrocardiogram, blood routine, urine routine, stool routine and blood biochemical indexes of the person who eats the test food have no obvious change, which indicates that the product has no adverse effect on the physical health of the subject.
4.3 No allergy or other adverse reactions are observed in the process of eating the composition soft capsule.
Claims (10)
1. The composition for relieving the visual fatigue is characterized by comprising astaxanthin and olive oil in a weight ratio of 1: 0.4-40.
2. The composition of claim 1, wherein the composition comprises astaxanthin and olive oil in a weight ratio of 1: 0.4 to 4.
3. The composition of claim 2, wherein the composition consists of astaxanthin and olive oil in a weight ratio of 1: 0.4 or 1: 4.
4. The composition according to any one of claims 1 to 3, wherein the composition is a granule, a tablet, a soft capsule, a drop pill, an oral liquid, a suspension or an emulsion; preferably a soft capsule.
5. Use of a composition according to any one of claims 1 to 3 for the preparation of a medicament or health product for relieving asthenopia or dry eye.
6. The soft capsule for relieving the visual fatigue is characterized in that the content of the soft capsule consists of astaxanthin and olive oil, wherein the weight ratio of the astaxanthin to the olive oil is 1: 0.4-40.
7. The soft capsule according to claim 6, wherein the weight ratio of astaxanthin to olive oil is 1: (0.4-4).
8. The soft capsule according to claim 7, wherein the contents of the soft capsule consist of: 80-130 parts of astaxanthin and 430 parts of olive oil; the capsule shell is composed of the following raw materials: 470 and 540 parts of gelatin, 220 and 280 parts of glycerol and 470 and 540 parts of purified water.
Preferably, the content of the soft capsule consists of the following raw materials: 90-120 parts of astaxanthin and 420 parts of olive oil 370-; the capsule skin comprises the following raw materials: 480 parts of gelatin, 270 parts of glycerol, and 480 parts of purified water;
or the content of the soft capsule consists of the following raw materials: 95-110 parts of astaxanthin and 410 parts of olive oil; the capsule skin comprises the following raw materials: 510 parts of gelatin 490-containing material, 260 parts of glycerol 240-containing material and 510 parts of purified water 490-containing material.
9. The soft capsule of claim 8, wherein the soft capsule contents consist of: 100 parts of astaxanthin and 400 parts of olive oil; the capsule skin comprises the following raw materials: 500 parts by weight of gelatin, 250 parts by weight of glycerol and 500 parts by weight of purified water.
10. The process for the preparation of the soft capsules according to any one of claims 6 to 9, comprising the steps of:
step a, preparation of contents: mixing astaxanthin and olive oil to obtain a content material liquid for later use;
step b, sol: weighing according to a certain proportion, firstly adding purified water and glycerol, heating and stirring, then adding gelatin until the gelatin is completely dissolved for later use;
step c, pelleting: and c, pelleting and shaping the content prepared in the step a and the glue solution prepared in the step b to prepare the soft capsule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910316791.1A CN111820409A (en) | 2019-04-18 | 2019-04-18 | Composition for relieving visual fatigue and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910316791.1A CN111820409A (en) | 2019-04-18 | 2019-04-18 | Composition for relieving visual fatigue and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111820409A true CN111820409A (en) | 2020-10-27 |
Family
ID=72915146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910316791.1A Pending CN111820409A (en) | 2019-04-18 | 2019-04-18 | Composition for relieving visual fatigue and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111820409A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114376229A (en) * | 2022-01-19 | 2022-04-22 | 中国科学院兰州化学物理研究所 | Microcapsule using medlar fruit oil and olive oil as core materials |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102389115A (en) * | 2011-11-03 | 2012-03-28 | 云南绿A生物工程有限公司 | Health food for alleviating visual fatigue and preparation method and application thereof |
CN104474018A (en) * | 2014-12-22 | 2015-04-01 | 威海百合生物技术股份有限公司 | Health-care soft capsule for relieving asthenopia |
CN104824510A (en) * | 2015-05-13 | 2015-08-12 | 宁波北仑戌鸿农业科技有限公司 | Health food with eyesight protection function |
CN107307418A (en) * | 2017-07-01 | 2017-11-03 | 山东健康源生物工程有限公司 | It is a kind of to be used to alleviate cowberry vitamin A soft capsule of visual fatigue and preparation method thereof |
US20180042978A1 (en) * | 2008-04-10 | 2018-02-15 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus |
CN108078974A (en) * | 2018-02-12 | 2018-05-29 | 成都图径生物科技有限公司 | Composition for relieving asthenopia containing theanine, γ-aminobutyric acid and astaxanthin |
CN108902958A (en) * | 2018-07-20 | 2018-11-30 | 深圳市博奥生物科技有限公司 | A kind of astaxanthin soft capsule and preparation method thereof |
-
2019
- 2019-04-18 CN CN201910316791.1A patent/CN111820409A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180042978A1 (en) * | 2008-04-10 | 2018-02-15 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus |
CN102389115A (en) * | 2011-11-03 | 2012-03-28 | 云南绿A生物工程有限公司 | Health food for alleviating visual fatigue and preparation method and application thereof |
CN104474018A (en) * | 2014-12-22 | 2015-04-01 | 威海百合生物技术股份有限公司 | Health-care soft capsule for relieving asthenopia |
CN104824510A (en) * | 2015-05-13 | 2015-08-12 | 宁波北仑戌鸿农业科技有限公司 | Health food with eyesight protection function |
CN107307418A (en) * | 2017-07-01 | 2017-11-03 | 山东健康源生物工程有限公司 | It is a kind of to be used to alleviate cowberry vitamin A soft capsule of visual fatigue and preparation method thereof |
CN108078974A (en) * | 2018-02-12 | 2018-05-29 | 成都图径生物科技有限公司 | Composition for relieving asthenopia containing theanine, γ-aminobutyric acid and astaxanthin |
CN108902958A (en) * | 2018-07-20 | 2018-11-30 | 深圳市博奥生物科技有限公司 | A kind of astaxanthin soft capsule and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
RICHARD M. CLARK 等: ""A Comparison of Lycopene and Astaxanthin Absorption "from Corn Oil and Olive Oil Emulsions", 《LIPIDS》 * |
国家食品药品监督管理总局 等编写: "《科学食用保健康:保健食品的选择》", 28 February 2015, 中国医药科技出版社 * |
李婷: ""雨生红球藻中虾青素的提取及抗氧化活性研究"", 《中国优秀博硕士学位论文全文数据库(硕士) 医药卫生科技辑》 * |
臧瑾: ""虾青素对酒精性脂肪肝的作用"", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114376229A (en) * | 2022-01-19 | 2022-04-22 | 中国科学院兰州化学物理研究所 | Microcapsule using medlar fruit oil and olive oil as core materials |
CN114376229B (en) * | 2022-01-19 | 2023-06-13 | 中国科学院兰州化学物理研究所 | Microcapsule using Lycium barbarum fruit oil and olive oil as core materials |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
LEROY et al. | Clinical definition of the Hurler-Hunter phenotypes: A review of 50 patients | |
CN101595977B (en) | Formula food beneficial to eye health and application thereof | |
WO2015172608A1 (en) | Capsule for assisting in reducing blood fat and preparation method therefor | |
WO2015127874A1 (en) | Traditional chinese medicine composition for treating type ii diabetes, and preparation and uses thereof | |
CN100420391C (en) | Health-care food with anti-oxidation and lowering weight functions | |
Gibberd et al. | Heredopathia atactica polyneuritiformis: Refsum's disease | |
CN102090630A (en) | Health-care product for enhancing antioxidation of human bodies and preparation method thereof | |
CN107951955A (en) | A kind of compound for alleviating asthenopia | |
CN103316032B (en) | Compositions containing hydroxytyrosol and application thereof | |
CN108685974A (en) | A kind of cowberry lutein piece and preparation method thereof | |
CN108902973A (en) | A kind of cowberry lutein particle and preparation method thereof | |
CN101356972B (en) | Anti-fatigue anti-hypoxia sports health food | |
CN111820409A (en) | Composition for relieving visual fatigue and preparation method thereof | |
CN1785054A (en) | Health-care food having anti-oxidation function and its prepn. method | |
CN101168051A (en) | Application of sea collagen peptide as preparation of anti-oxidation medicine, health-care food, food or cosmetics | |
CN103446166B (en) | Hepatic function remedial agent | |
CN105533316A (en) | Production method of blueberry chewable tablets for alleviating visual fatigue | |
CN108514114A (en) | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory | |
CN102150860B (en) | Composition for easing visual fatigue and assisting in improving memory | |
CN1973873A (en) | Eye health food capsule | |
CN108812916A (en) | A kind of hunchbacked milk tablet and its preparation with auxiliary hyperglycemic function | |
CN113197304A (en) | Health food for improving sleep and preparation method thereof | |
CN108902974A (en) | A kind of cowberry lutein capsule and preparation method thereof | |
CN112385755A (en) | A preparation method of fruit and vegetable beverage with eyesight protecting effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201027 |
|
RJ01 | Rejection of invention patent application after publication |